Dewpoint Therapeutics launches with $60m Series A to advance proprietary platform for drugging condensates

Image: Dewpoint Therapeutics launches with $60m Series A to advance proprietary platform for drugging condensates. Photo: courtesy of Photokanok/FreeDigitalPhotos.net.